Lamictal IR Experience Impresses Advisory Committee, Not XR Trial Design
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee members recommend Lamictal XR as a monotherapy for partial seizures, relying on the knowledge that the immediate-release version of the drug works for the indication.
You may also be interested in...
FDA Advisory Committee Waivers Reflect Recruitment Challenges
Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.
FDA Advisory Committee Waivers Reflect Recruitment Challenges
Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.